HRP20230697T1 - Liječenje karcinoma - Google Patents
Liječenje karcinoma Download PDFInfo
- Publication number
- HRP20230697T1 HRP20230697T1 HRP20230697TT HRP20230697T HRP20230697T1 HR P20230697 T1 HRP20230697 T1 HR P20230697T1 HR P20230697T T HRP20230697T T HR P20230697TT HR P20230697 T HRP20230697 T HR P20230697T HR P20230697 T1 HRP20230697 T1 HR P20230697T1
- Authority
- HR
- Croatia
- Prior art keywords
- erdafitinib
- use according
- fgfr3
- phosphate levels
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Laminated Bodies (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Prostheses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455211P | 2017-02-06 | 2017-02-06 | |
| EP17209098 | 2017-12-20 | ||
| EP18702299.1A EP3576740B1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
| PCT/EP2018/052694 WO2018141921A1 (en) | 2017-02-06 | 2018-02-02 | Cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230697T1 true HRP20230697T1 (hr) | 2023-10-13 |
Family
ID=61094531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230697TT HRP20230697T1 (hr) | 2017-02-06 | 2018-02-02 | Liječenje karcinoma |
Country Status (26)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200208224A1 (en) * | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| SG11201702381QA (en) | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| CA3049737A1 (en) * | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Cancer treatment |
| BR112021015686A2 (pt) * | 2019-02-12 | 2021-10-26 | Janssen Pharmaceutica N.V. | Tratamento de câncer |
| MX2021011926A (es) * | 2019-03-29 | 2021-11-03 | Janssen Pharmaceutica Nv | Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. |
| US20220175768A1 (en) * | 2019-03-29 | 2022-06-09 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| PH12022552093A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer |
| WO2021201201A1 (ja) * | 2020-04-03 | 2021-10-07 | インタープロテイン株式会社 | 新型コロナウイルス感染症(covid-19)の予防または治療剤および医薬組成物 |
| EP4719420A1 (en) * | 2023-05-24 | 2026-04-08 | Janssen Pharmaceutica NV | Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI719960B (zh) * | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CA3049737A1 (en) * | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Cancer treatment |
-
2018
- 2018-02-02 CA CA3049737A patent/CA3049737A1/en active Pending
- 2018-02-02 DK DK18702299.1T patent/DK3576740T3/da active
- 2018-02-02 HR HRP20230697TT patent/HRP20230697T1/hr unknown
- 2018-02-02 PL PL18702299.1T patent/PL3576740T3/pl unknown
- 2018-02-02 KR KR1020197024552A patent/KR20190110581A/ko not_active Ceased
- 2018-02-02 EP EP23178682.3A patent/EP4286005A3/en active Pending
- 2018-02-02 CN CN201880008126.XA patent/CN110198716A/zh active Pending
- 2018-02-02 NZ NZ796822A patent/NZ796822A/en unknown
- 2018-02-02 EP EP18702299.1A patent/EP3576740B1/en active Active
- 2018-02-02 SM SM20230233T patent/SMT202300233T1/it unknown
- 2018-02-02 KR KR1020257014703A patent/KR20250069693A/ko active Pending
- 2018-02-02 SG SG11201907199QA patent/SG11201907199QA/en unknown
- 2018-02-02 MX MX2019009304A patent/MX2019009304A/es unknown
- 2018-02-02 SI SI201830961T patent/SI3576740T1/sl unknown
- 2018-02-02 HU HUE18702299A patent/HUE062453T2/hu unknown
- 2018-02-02 JP JP2019541398A patent/JP2020505425A/ja not_active Withdrawn
- 2018-02-02 AU AU2018216969A patent/AU2018216969B2/en active Active
- 2018-02-02 LT LTEPPCT/EP2018/052694T patent/LT3576740T/lt unknown
- 2018-02-02 UA UAA201909567A patent/UA126336C2/uk unknown
- 2018-02-02 US US16/483,579 patent/US11077106B2/en active Active
- 2018-02-02 ES ES18702299T patent/ES2953005T3/es active Active
- 2018-02-02 SG SG10202105110VA patent/SG10202105110VA/en unknown
- 2018-02-02 JO JOJO/P/2019/0190A patent/JOP20190190B1/ar active
- 2018-02-02 TW TW112109467A patent/TWI874925B/zh active
- 2018-02-02 FI FIEP18702299.1T patent/FI3576740T3/fi active
- 2018-02-02 RS RS20230615A patent/RS64778B1/sr unknown
- 2018-02-02 BR BR112019016043-4A patent/BR112019016043A2/pt not_active Application Discontinuation
-
2019
- 2019-08-04 IL IL268463A patent/IL268463A/en unknown
- 2019-08-05 PH PH12019501885A patent/PH12019501885A1/en unknown
- 2019-08-05 MX MX2022007955A patent/MX2022007955A/es unknown
-
2021
- 2021-06-28 US US17/360,618 patent/US20220110935A1/en not_active Abandoned
-
2022
- 2022-11-28 JP JP2022189239A patent/JP7668777B2/ja active Active
-
2024
- 2024-03-22 AU AU2024201871A patent/AU2024201871B2/en active Active
- 2024-11-11 JP JP2024196985A patent/JP7884578B2/ja active Active
-
2025
- 2025-08-18 US US19/302,199 patent/US20260199326A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3576740T3 (fi) | Syöpähoito | |
| Kozakiewicz et al. | Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma | |
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| JP2020505425A5 (cg-RX-API-DMAC7.html) | ||
| Sahu et al. | Targeted therapy in biliary tract cancers—current limitations and potentials in the future | |
| Shepherd et al. | Angiogenesis inhibitors under study for the treatment of lung cancer | |
| RU2009127351A (ru) | Комбинации антифолатного агента в лечении рака | |
| HRP20211244T1 (hr) | Farmaceutske kompozicije koje sadrže n-(3,5-dimetoksifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)kvinoksalin-6-il]etan-1,2-diamin | |
| US11007194B2 (en) | Method of treating a proliferative disease | |
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| ZA202203668B (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| Aparo et al. | Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy | |
| Martina Ferrari et al. | Pyrazolopyrimidine derivatives as antineoplastic agents: With a special focus on thyroid cancer | |
| FI3773595T3 (fi) | Syöpälääkekoostumuksia yhdistelmähoitoon | |
| CA2649792A1 (en) | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof | |
| Jeong et al. | Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation | |
| TW202114689A (zh) | Cdk4/6抑制劑與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| Domagala et al. | Iniparib in metastatic triple-negative breast cancer | |
| AU2006203428B2 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| Miranda et al. | Targeted fibroblast growth factor receptor (FGFR) inhibition in recurrent, metastatic anal carcinoma: a case report | |
| CN103864784A (zh) | 一种新型氮杂吲哚-2-酮类fgfr1抑制剂及其抗肿瘤活性 | |
| Kim et al. | Reninoma Masked by the Use of an Angiotensin Receptor Blocker (Case Report) | |
| CN103251586B (zh) | 抗血管发生药物为基础的抗肿瘤组合物 | |
| Braileanu | Teaching an Old Dog New Tricks: Introducing a Hypothetical Mechanism of Synergy Between Metformin and New Generation mTOR Inhibitors in the Fight Against Cancer | |
| Toyokawa | Hyperammonaemia and impaired consciousness: case report |